title: Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
abstract: Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile. The aim of this single blind, randomized clinical trial was to compare the efficacy of pantoprazole (PAN) 40 mg/day and omeprazole (OME) 20 mg/day in patients with grade I and II GERD (Savary-Miller classification). A total of 120 patients were included (PAN = 60 and OME = 60). In the per protocol/analysis, healing rates at 4 weeks were 76.3% PAN and 71.2% OME (ns), and at 8 weeks 94.7% PAN and 92.9% OME (ns). In the intention to treat analysis, healing rates at 4 weeks were 75% PAN and 70% OME (ns), and at 8 weeks 90% PAN and 86.6% OME (ns). Both pantoprazole and omeprazole were well tolerated with no serious drug related adverse events. Pantoprazole 40 mg/day was found to be safe and effective therapy comparable to omeprazole 20 mg/day in the short-term treatment for reflux esophagitis (grade I and II).
authors.affiliation: Department of Medicine, University Hospital, Osijek, Croatia.
authors.forename: A
authors.initials: A
authors.lastname: Vcev
authors.forename: D
authors.initials: D
authors.lastname: Stimac
authors.forename: A
authors.initials: A
authors.lastname: Vceva
authors.forename: B
authors.initials: B
authors.lastname: Takac
authors.forename: A
authors.initials: A
authors.lastname: Ivandić
authors.forename: D
authors.initials: D
authors.lastname: Pezerović
authors.forename: D
authors.initials: D
authors.lastname: Horvat
authors.forename: P
authors.initials: P
authors.lastname: Nedić
authors.forename: Z
authors.initials: Z
authors.lastname: Kotromanović
authors.forename: Z
authors.initials: Z
authors.lastname: Maksimović
authors.forename: Z
authors.initials: Z
authors.lastname: Vranjes
authors.forename: J
authors.initials: J
authors.lastname: Males
authors.forename: D
authors.initials: D
authors.lastname: Jurisić-Orzen
authors.forename: I
authors.initials: I
authors.lastname: Vladika
authors.forename: T
authors.initials: T
authors.lastname: Stimac
authors.forename: B
authors.initials: B
authors.lastname: Mandić
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D000077402:Pantoprazole; D016037:Single-Blind Method; D013454:Sulfoxides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole